Hypertension Management Calculator — 2025 AHA/ACC · JNC 8 · ADA 2024
Hypertension Management Decision Support
2025 AHA/ACC ADA 2024 JNC 8

Hypertension Management Decision Support Calculator

Enter blood pressure readings, patient demographics, and comorbidities to generate evidence-based staging, individualized drug therapy recommendations, BP goals, and a copy-ready clinical note per current guidelines.

2025 AHA/ACC HTN Guideline JNC 8 Evidence Review ADA 2024 Diabetes Standards PREVENT Risk Calculator ESH/ESC 2023 CKD / Compelling Indications
1
Blood Pressure Readings
Average of ≥2 properly measured readings on ≥2 occasions
📏 Proper Measurement Technique
Patient seated quietly for ≥5 min, feet flat, back supported. Arm at heart level. Validated electronic device. Average of 2 readings taken 1–2 minutes apart. Confirm with out-of-office readings (home BP or 24-hour ABPM) before initiating therapy.
AAverage BP Reading
SBP
DBP
BOut-of-Office BP  If available — helps confirm white coat vs. masked HTN
CPatient Demographics
DAuto-Staged BP Category  Set from readings — override if needed
🟢
Normal
<120/<80
🟡
Elevated
120–129/<80
🟠
Stage 1
130–139/80–89
🔴
Stage 2
≥140/≥90
🚨
Crisis
≥180/≥120
2
Comorbidities & Compelling Indications
Drive first-line drug class selection — critical for individualized therapy
💡 Why Compelling Indications Matter
2025 AHA/ACC and JNC 8: Certain comorbidities mandate specific drug classes regardless of BP stage — these are "compelling indications." For example, post-MI patients require beta-blockers + ACEi/ARB, CKD patients require ACEi/ARB to slow progression, and heart failure patients require specific combinations. These override standard monotherapy selection.
BLifestyle & Risk Factors
3
Laboratory Values
Guides drug selection, contraindications, and goal adjustment
4
Current Antihypertensive Therapy
Determines whether to initiate, intensify, or add agents
BCurrent Drug Classes (check all that currently apply — treatment status is determined automatically)
5
Secondary Hypertension Screening
Consider if young, resistant, or unusual features present
🔍 When to Suspect Secondary HTN
Age <30 with no family history, resistant HTN on ≥3 agents, hypokalemia (especially on ACEi/ARB), onset after age 55 (renal artery stenosis), cushingoid features, or episodic HTN with diaphoresis (pheochromocytoma).
BSecondary Cause Clues
6
Lifestyle Counseling & Note Options
Document counseling provided today
ACounseling Provided Today
Live Decision Support
🩺

Enter the systolic and diastolic blood pressure above to generate evidence-based staging and treatment recommendations.

Comorbidities, labs, and current medications refine recommendations automatically.

⚠️ Clinical Decision Support Tool — Not a substitute for clinical judgment. HTNCalc implements the 2025 AHA/ACC Hypertension Guideline (Jones DW et al., JACC/Hypertension 2025), JNC 8, and ADA 2024 Standards of Care. Incorporates PREVENT risk calculator guidance, updated primary aldosteronism screening, and pregnancy recommendations. Recommendations must be individualized to the patient. Always verify drug dosing, interactions, contraindications, and allergy status. HTNCalc does not collect or transmit patient data.